Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.
A genetic mutation pattern predicts which gastric cancer patients benefit most from immunotherapy plus chemotherapy, helping tailor treatment choices.
This study investigates whether the insertion/deletion mutation rate can predict treatment response in gastric cancer patients receiving nivolumab combined with chemotherapy. The genomic biomarker showed predictive value, potentially helping select patients for immunotherapy-chemotherapy combinations.
What the study was
- Study design
- Retrospective biomarker analysis
- Population
- Gastric cancer patients treated with nivolumab + chemotherapy
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of gastric cancer
Why it surfaced
Novel biomarker for immunotherapy prediction in gastric cancer. Retrospective design limits evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.